Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack
This study provides Class II evidence that among patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, the net benefit of clopidogrel-aspirin initiated within 72 hours of symptom onset was pronounced in the first week and continued to a lesser degree in the following 2 weeks, outweighing the low but ongoing hemorrhagic risk.
Authors
- S. Claiborne Johnston (ORCID: https://orcid.org/0000-0002-2912-0714)
- Chunjuan Wang (ORCID: https://orcid.org/0000-0002-1627-5004)
- Pierre Amarenco (ORCID: https://orcid.org/0000-0002-3842-1236)
- Yingying Yang (ORCID: https://orcid.org/0000-0001-9431-9925)
- Shangrong Han (ORCID: https://orcid.org/0000-0003-2608-484X)
- Philip M. Bath (ORCID: https://orcid.org/0000-0003-2734-5132)
- Yuesong Pan (ORCID: https://orcid.org/0000-0003-3082-6789)
- Yongjun Wang (ORCID: https://orcid.org/0000-0002-9976-2341)
- Yilong Wang (ORCID: https://orcid.org/0000-0002-3267-0039)
- Tingting Wang (ORCID: https://orcid.org/0000-0002-3809-2209)
- Weiqi Chen (ORCID: https://orcid.org/0000-0002-2551-9314)
- Jing Jing (ORCID: https://orcid.org/0000-0001-9822-5758)
- Ling Guan (ORCID: https://orcid.org/0000-0003-3381-8370)
- Ying Gao (ORCID: https://orcid.org/0000-0002-5409-7675)
- Hongyi Yan (ORCID: https://orcid.org/0000-0003-4185-0506)
- Xuan Wang (ORCID: https://orcid.org/0000-0002-4160-0761)
Institutions
- Inserm (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- National Clinical Research (US)
- Laboratoire de Recherche Vasculaire Translationnelle (FR)
Publication Details
- Journal
- Neurology
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1212/wnl.0000000000209845
- Citations
- 7
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Kowa Company
- Institut National de la Santé et de la Recherche Médicale
- Novo Nordisk
- University of California, San Francisco